Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2014-06-30
2018-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
e-BioMatrix Canada Registry
NCT01915628
Coronary Bifurcation Lesions Treated With Biguard Stent System
NCT02597283
Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft System
NCT04023370
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
NCT02871622
Bare Metal Bifurcation Stent Clinical Trial in Humans
NCT00607321
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Clinical relevance The European Union has a focus on and encourages the conductance of post marketing surveillance studies of medical devices 3. This focus should be seen in the light of limitations to clinical data available in the pre-market phase owing to duration of pre-market clinical investigations, the number of subjects and investigators involved in an investigation, the relative heterogeneity of subjects and investigators and the controlled setting of a clinical investigation versus the full range of clinical conditions encountered in general medical practice. The extent of the data that can be gathered in the pre-market phase does not necessarily enable detection of rare complications or problems that only become apparent after widespread or long term use of the device. Because the study device (BioMatrix NeoFlex™) is a CE-marked updated version of the BioMatrix Flex stent it is important to document that the assumed improvements in delivery design also reflect improvements in a clinical setting.
Patients and methods
Patients A total of 6000 patients will be included in the VALIDATE SWEDEHEART trial. 3000 STEMI and 3000 NSTEMI. The ambition is that approximately 1000 of these patients are also included in the BASIC VALIDATE stent registry. In addition, and in order to achieve post-market information from the entire spectrum of PCI, another 1000 patients with stable angina pectoris, STEMI or NSTEMI will be included in the registry at VALIDATE SWEDEHEART centers but unrelated to the VALIDATE SWEDEHEART trial.
Treatment strategy During the index procedure, only BioMatrix NeoFlex™ stents will be implanted. The investigator will choose the appropriate length and diameter of the stents to be implanted by visual estimate. The choice of the length of the stent should ensure complete coverage of the lesion. In case of insufficient stent expansion, post-dilatation is highly recommended. In the event that a staged procedure is expected or planned it is recommended NOT to include the patient in the BASIC VALIDATE registry because the nature of follow-up of patients (registry only) means that staged procedures will be classified as events ("repeat" revascularizations).
After the index PCI, lifelong acetylsalicylic acid in a dose of 75-160 mg per day will be prescribed. Duration and choice of post-PCI P2Y12 inhibition is left to the discretion of the treating physician.
Endpoints Primary endpoint A composite of time to death, myocardial infarction, stent thrombosis or repeat revascularization at 12 months.
Secondary endpoints
* Time to death at 1, 3 and 5 years.
* Time to myocardial infarction at 1, 3 and 5 years.
* Time to stent thrombosis at 1, 3 and 5 years.
* Time to repeat revascularization at 1, 3 and 5 years.
* Analysis of the primary endpoint in the NSTEMI and STEMI groups separately.
All endpoint results will be compared to matched populations of patients treated with drug-eluting coronary stents as documented in the SCAAR/SWEDEHEART registries.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ischemic heart disease
Patients undergoing percutaneous coronary intervention (PCI)
Coronary stenting with CE-marked stent
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coronary stenting with CE-marked stent
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a diagnosis of STEMI as defined by chest pain suggestive for myocardial ischemia for at least 30 minutes before hospital admission, time from onset of symptoms of less than 24 hours, and an ECG with new ST-segment elevation in two or more contiguous leads of ≥0.2 mV in leads V2-V3 and/or ≥0.1 mV in other leads or a probable new-onset left bundle branch block.
* Patients with stable coronary artery disease
* PCI of culprit lesion is intended.
* Age above 18 years
Exclusion Criteria
* Known terminal disease with life expectancy less than one year.
* Patients with known ongoing bleeding
* Patients with uncontrolled hypertension in the opinion of the investigator
* Patients with known subacute bacterial endocarditis
* Patients with known severe renal (GFR \< 30 ml/min) and /or liver dysfunctions
* Patients with known thrombocytopenia or thrombocyte function defects
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biosensors International
OTHER
Region Örebro County
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ole Frobert, MD, PhD
Adjunct Professor, MD, PhD
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Prospective registry
Identifier Type: -
Identifier Source: secondary_id
BASIC VALIDATE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.